Millendo Therapeutics, Inc.
NASDAQ: MLND0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Julia Owens
- Employees
- 12
- Headquarters
- Ann Arbor, United States
- IPO year
- 2012
- Market cap
- $11.1M
- Website
- http://www.millendo.com
Loading MLND…
Loading profile data…Frequently asked questions about MLND
What does Millendo Therapeutics, Inc. (MLND) do?
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for pati...
Where does MLND trade?
Millendo Therapeutics, Inc. (MLND) trades on the NASDAQ Capital Market.
What sector is MLND in?
Millendo Therapeutics, Inc. (MLND) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Millendo Therapeutics, Inc.?
Julia Owens is the chief executive officer of Millendo Therapeutics, Inc. (MLND).
Where is Millendo Therapeutics, Inc. headquartered?
Millendo Therapeutics, Inc. is headquartered in United States.
Does MLND pay a dividend?
Millendo Therapeutics, Inc. (MLND) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MLND go public?
Millendo Therapeutics, Inc. (MLND) completed its initial public offering in 2012.